CNBX Pharmaceuticals Inc is developing a platform that leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based cancer therapies tailored to each patients specific profile.

By developing tools to assess effectiveness on a personalized basis, Cannabics seeks to make cannabinoids part of the future of cancer therapy.In Israel, G.R.I.N Ultra Ltd operates as the company's R&D wholly-owned subsidiary where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.